Related Experiment Video
Updated: Jun 15, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Updates on cytochrome p450-mediated cardiovascular drug interactions
Judy W M Cheng1, William H Frishman, Wilbert S Aronow
1Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, Mt. Sinai Medical Center, New York, New York.
Disease-A-Month : DM
|March 2, 2010
Summary
Cytochrome P450 (CYP450) enzymes are crucial for drug metabolism. Understanding CYP450 drug interactions is vital for preventing serious cardiovascular side effects when using multiple medications.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Medicine
Background:
- Cytochrome P450 (CYP450) enzymes are key hemoproteins involved in metabolizing endogenous compounds and xenobiotics.
- Cardiovascular drugs frequently interact with CYP450 enzymes as substrates, inhibitors, or inducers.
- Co-administration of CYP450-interacting agents can lead to significant drug interactions.
Purpose of the Study:
- To review CYP450-mediated drug interactions relevant to cardiovascular disease management.
- To discuss noncardiovascular drug interactions causing cardiovascular side effects.
- To outline principles for predicting drug interactions.
Main Methods:
- Literature review of CYP450-mediated drug interactions.
- Analysis of clinical consequences of drug interactions.
- Discussion of predictive principles for drug interactions.
Main Results:
- CYP450 enzymes significantly influence the efficacy and safety of cardiovascular medications.
- Interactions can manifest as altered drug levels, leading to toxicity or therapeutic failure.
- Noncardiovascular drugs can also precipitate cardiovascular adverse events via CYP450 pathways.
Conclusions:
- Awareness of CYP450 enzyme activity is essential for safe prescribing of cardiovascular drugs.
- Predicting and managing drug interactions involving CYP450 is critical for patient outcomes.
- This review provides a framework for understanding and mitigating CYP450-related drug interactions.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...